Using targeted delivery of Bevacizumab for treating recurrent brain tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the safety and efficacy of repeated super-selective intraarterial cerebral infusion of Bevacizumab (Avastin) for patients with relapsed glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA). The study aims to determine if this method can improve progression-free survival and overall survival compared to the standard intravenous administration. Participants will receive Bevacizumab through a targeted intraarterial approach, which may enhance drug delivery across the blood-brain barrier. The trial is designed as a two-arm open-label, non-randomized study, building on previous findings that indicated the safety of this delivery technique.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years of age or older.
* Patients with a documented histologic diagnosis of relapsed or refractory glioblastoma multiforme (GBM), anaplastic astrocytoma (AA) or anaplastic mixed oligoastrocytoma (AOA).
* Patients must have at least one confirmed and evaluable tumor site. A confirmed tumor site is one in which is biopsy-proven.
* Patients must have a Karnofsky performance status 70% (or the equivalent ECOG level of 0-2).
* Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period.

Exclusion Criteria:

* Previous treatment with greater than 2 cycles of Bevacizumab at 10mg/kg (2 IV Infusions).
* Women who are pregnant or lactating.
* Patients with significant inter-current medical or psychiatric conditions that would place them at increased risk or affect their ability to receive or comply with treatment or post-treatment clinical monitoring.

Where it's running

• Lenox Hill Brain Tumor Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: John Boockvar, MD — Feinstein Institute for Medical Research
• Study coordinator: John Boockvar, MD
• Email: jboockvar@nshs.edu
• Phone: 212-434-3905

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment for young patients with relapsed or refractory brain tumors

  This study is testing a new way to deliver cancer drugs directly to the brain tumors of young patients under 22 who have not responded to other treatments, to see if it helps them feel better.

  Recruiting Phase 1/2 University of Miami · Miami, Florida · NCT05956821

• Evaluating Bevacizumab with Focused Ultrasound for Recurrent Glioblastoma

  This study is testing if adding focused ultrasound to the standard treatment of Bevacizumab can help people with recurrent glioblastoma feel better and live longer.

  Recruiting at 2 sites Phase 3 NaviFUS Corporation · Taipei and 1 other locations · NCT06496971

• Lorlatinib for newly diagnosed high-grade glioma with ALK or ROS1 fusions

  This trial will test whether the oral medicine lorlatinib helps children and young adults (ages 1–21) with newly diagnosed high-grade gliomas that have ALK or ROS1 fusions, given alone, with chemotherapy, or after radiation.

  Recruiting at 2 sites Early Phase 1 Nationwide Children's Hospital · Aurora, Colorado and 17 other locations · NCT06333899

• Combining ribociclib and everolimus for treating high-grade gliomas in young patients

  This study is testing if a combination of two drugs, ribociclib and everolimus, can help young patients with high-grade gliomas live longer and feel better after their initial treatment.

  Recruiting at 12 sites Phase 2 Nationwide Children's Hospital · Aurora, Colorado and 19 other locations · NCT05843253

• Genetic profiling for pediatric high-grade glioma treatment eligibility

  This study is testing if genetic testing of brain tumors in children and young adults with high-grade gliomas can help match them to the best treatment options.

  Recruiting at 13 sites Nationwide Children's Hospital · Aurora, Colorado and 21 other locations · NCT05839379

• Infusion of Bevacizumab with Chemotherapy and Radiation for Newly Diagnosed Glioblastoma

  This study is testing if adding a special infusion of Bevacizumab to standard chemotherapy and radiation can help people with newly diagnosed glioblastoma live longer and feel better.

  Recruiting Phase 3 Northwell Health · New York, New York · NCT05271240

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.